UFP Technologies, Inc.

NasdaqCM:UFPT Stock Report

Market Cap: US$2.4b

UFP Technologies Valuation

Is UFPT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of UFPT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: UFPT ($309.45) is trading above our estimate of fair value ($180.87)

Significantly Below Fair Value: UFPT is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UFPT?

Key metric: As UFPT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for UFPT. This is calculated by dividing UFPT's market cap by their current earnings.
What is UFPT's PE Ratio?
PE Ratio43.8x
EarningsUS$54.21m
Market CapUS$2.42b

Price to Earnings Ratio vs Peers

How does UFPT's PE Ratio compare to its peers?

The above table shows the PE ratio for UFPT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36.7x
VIVO Meridian Bioscience
35.2xn/aUS$1.5b
HAE Haemonetics
36.8x24.7%US$4.6b
STAA STAAR Surgical
61.7x34.2%US$1.4b
LNTH Lantheus Holdings
13.1x13.9%US$5.5b
UFPT UFP Technologies
43.8x16.9%US$2.4b

Price-To-Earnings vs Peers: UFPT is expensive based on its Price-To-Earnings Ratio (43.8x) compared to the peer average (37.2x).

Price to Earnings Ratio vs Industry

How does UFPT's PE Ratio compare vs other companies in the US Medical Equipment Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
1.4xn/aUS$13.50m
ODYY Odyssey Health
0.2xn/aUS$1.92m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
UTRS Minerva Surgical
n/an/aUS$8.00
No more companies available in this PE range
UFPT 43.8xIndustry Avg. 36.9xNo. of Companies9PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: UFPT is expensive based on its Price-To-Earnings Ratio (43.8x) compared to the US Medical Equipment industry average (37.2x).

Price to Earnings Ratio vs Fair Ratio

What is UFPT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UFPT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio43.8x
Fair PE Ratio31.5x

Price-To-Earnings vs Fair Ratio: UFPT is expensive based on its Price-To-Earnings Ratio (43.8x) compared to the estimated Fair Price-To-Earnings Ratio (31.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst UFPT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$309.45
US$381.00
+23.1%
2.9%US$392.00US$370.00n/a2
Nov ’25US$272.66
US$378.50
+38.8%
3.6%US$392.00US$365.00n/a2
Oct ’25US$308.19
US$378.50
+22.8%
3.6%US$392.00US$365.00n/a2
Sep ’25US$341.23
US$378.50
+10.9%
3.6%US$392.00US$365.00n/a2
Aug ’25US$325.66
US$378.50
+16.2%
3.6%US$392.00US$365.00n/a2
Jun ’25US$260.36
US$262.50
+0.8%
2.9%US$270.00US$255.00n/a2
May ’25US$235.84
US$262.50
+11.3%
2.9%US$270.00US$255.00n/a2
Apr ’25US$250.83
US$243.00
-3.1%
4.9%US$255.00US$231.00n/a2
Sep ’24US$175.40
US$223.00
+27.1%
0.4%US$224.00US$222.00US$341.232
Aug ’24US$191.40
US$223.00
+16.5%
0.4%US$224.00US$222.00US$325.662
Jul ’24US$193.85
US$223.00
+15.0%
0.4%US$224.00US$222.00US$289.092
Jun ’24US$158.46
US$164.00
+3.5%
4.3%US$171.00US$157.00US$260.362
May ’24US$139.13
US$134.00
-3.7%
2.2%US$137.00US$131.00US$235.842
Apr ’24US$129.84
US$134.00
+3.2%
2.2%US$137.00US$131.00US$250.832
Mar ’24US$117.96
US$125.50
+6.4%
1.2%US$127.00US$124.00US$216.802
Feb ’24US$110.05
US$125.50
+14.0%
1.2%US$127.00US$124.00US$177.592
Jan ’24US$117.89
US$125.50
+6.5%
1.2%US$127.00US$124.00US$172.042
Dec ’23US$122.30
US$125.50
+2.6%
1.2%US$127.00US$124.00US$166.672

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Elevance Health

US$95.3b

Operates as a health benefits company in the United States.

ELV

US$407.04

7D

-5.2%

1Y

-12.2%

CVS Health

US$68.3b

Provides health solutions in the United States.

CVS

US$55.09

7D

-3.5%

1Y

-19.3%

Enhabit

US$382.7m

Provides home health and hospice services in the United States.

EHAB

US$7.44

7D

-6.1%

1Y

-23.2%